Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 2/20 | 0.48 |
| ▸ | CDK2 | P24941 | 6/20 | 0.47 |
| ▸ | CDK9 | P50750 | 5/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.47 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.47 |
| ▸ | CDK1 | P06493 | 2/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.47 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.47 |
| ▸ | CDC7 | O00311 | 8/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 6/20 | 0.46 |
| ▸ | PIM1 | P11309 | 6/20 | 0.46 |
| ▸ | PRKACA | P17612 | 6/20 | 0.46 |
| ▸ | GSK3B | P49841 | 6/20 | 0.46 |
| ▸ | HIPK2 | Q9H2X6 | 5/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 5/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12501060 | 0.90 | CDK2 (0.44) | TOP1CDK2CDK9CCNT1CCNA2 | |
| SCHEMBL3386630 | 0.90 | CDC7 (0.52) | CDK2CDK9CCNT1CCNA2CCNB2 | |
| SCHEMBL14877206 | 0.85 | CDC7 (0.46) | CDK2CDK9CCNT1CCNA2CCNB2 | |
| SCHEMBL3384274 | 0.85 | CDC7 (0.56) | CDK2CDK9CCNT1CCNA2CCNB2 | |
| SCHEMBL3386631 | 0.84 | CDC7 (0.47) | CDK2CDK9CCNT1CCNA2CCNB2 | |
| SCHEMBL857999 | 0.82 | CAMKK2 (0.59) | CDK2CDK9CCNT1CCNA2CCNB2 | |
| SCHEMBL15397128 | 0.81 | CDC7 (0.44) | CDK2CDK9CCNT1CCNA2CCNB2 | |
| SCHEMBL12501031 | 0.75 | CCNB2 (0.51) | CDK2CDK9CCNT1CCNA2CCNB2 | |
| SCHEMBL28052422 | 0.75 | TGFBR1 (0.49) | CDK2CDK9CCNT1CCNA2CCNB2 | |
| SCHEMBL3252733 | 0.74 | CCNB2 (0.74) | CDK2CCNB2CDK1CCNB1CCNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2585461-B1 | 2,4-DIARYL-SUBSTITUTED [1,8]NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GMBH (DE) | 2020-02-26 | — | — | EP | disclosed |
| EP-2585461-B1 | 2,4-DIARYL-SUBSTITUTED [1,8]NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GMBH (DE) | 2020-02-26 | — | — | EP | disclosed |
| US-8791113-B2 | 2,4-diaryl-substituted [1,8] naphthyridines as kinase inhibitors for use against cancer | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| US-8791113-B2 | 2,4-diaryl-substituted [1,8] naphthyridines as kinase inhibitors for use against cancer | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| US-20130102603-A1 | 2,4-DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-04-25 | — | — | US | disclosed |
| US-20130102603-A1 | 2,4-DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-04-25 | — | — | US | disclosed |
| WO-2012000595-A1 | 2,4- DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GMBH (DE) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102603-A1 | 2,4-DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | TGFBR1, TAB1, TGFBR2 | TOP1 939/4885CDK2 67/4885CDK9 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.